Gossamer Bio's (GOSS) Overweight Rating Reaffirmed at Cantor Fitzgerald

Key Points

• Gossamer Bio's stock maintains an "overweight" rating from Cantor Fitzgerald, while other analysts show mixed sentiments with ratings ranging from "buy" to "sell".
• The company's stock price has increased by 12.3%, with a current market capitalization of approximately $707.15 million.
• Gossamer Bio reported a quarterly earnings of ($0.17) EPS, beating estimates, and generated significant revenue of $11.49 million compared to the expected $4.12 million.

Gossamer Bio (NASDAQ:GOSS - Get Free Report)'s stock had its "overweight" rating reaffirmed by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other research analysts also recently issued reports on the company. Wall Street Zen downgraded Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Scotiabank started coverage on Gossamer Bio in a research note on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price objective on the stock. The Goldman Sachs Group boosted their price objective on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Finally, Wedbush boosted their price objective on Gossamer Bio from $4.00 to $5.00 and gave the company an "outperform" rating in a research note on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $8.50.

Gossamer Bio Stock Up 12.3%

Shares of GOSS opened at $3.11 on Thursday. The company has a market capitalization of $707.15 million, a PE ratio of -5.02 and a beta of 1.95. Gossamer Bio has a 12 month low of $0.66 and a 12 month high of $3.40. The stock's 50-day moving average price is $1.99 and its two-hundred day moving average price is $1.43. The company has a current ratio of 4.40, a quick ratio of 4.40 and a debt-to-equity ratio of 6.70.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.01. The firm had revenue of $11.49 million for the quarter, compared to the consensus estimate of $4.12 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%. On average, analysts anticipate that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP raised its stake in Gossamer Bio by 41.3% during the 4th quarter. Two Sigma Investments LP now owns 891,279 shares of the company's stock worth $806,000 after buying an additional 260,318 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in shares of Gossamer Bio during the first quarter valued at approximately $387,000. Two Sigma Advisers LP grew its holdings in Gossamer Bio by 44.7% during the fourth quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company's stock worth $1,047,000 after buying an additional 357,500 shares in the last quarter. Mackenzie Financial Corp grew its holdings in Gossamer Bio by 499.0% during the fourth quarter. Mackenzie Financial Corp now owns 299,815 shares of the company's stock worth $271,000 after buying an additional 249,765 shares in the last quarter. Finally, Millennium Management LLC raised its position in Gossamer Bio by 14.6% in the 4th quarter. Millennium Management LLC now owns 3,586,067 shares of the company's stock valued at $3,244,000 after buying an additional 457,179 shares during the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.